Skip to main content

Preventive health care measures before and after start of renal replacement therapy

Abstract

OBJECTIVE: To describe utilization of preventive health care measures in patients with chronic kidney disease (CKD), both in the year prior to onset of renal replacement therapy (RRT), and in the first year of RRT.

METHODS: We identified a large cohort of patients with CKD in the New Jersey Medicaid and Medicare programs with fixed enrollment into the cohort at 1 year prior to RRT. We applied commonly used quality assurance instruments (Health Plan Employer Data and Information Set measures) and defined levels and correlates of use of preventive care measures before and after RRT. These included mammography, Pap smear testing, prostate cancer screening, diabetic eye exams, and glycosylated hemoglobin testing (HbA1c). We employed logistic regression models with adjustment for age, race, gender, comorbidity, timing of first nephrologist contact, socioeconomic status, and calendar year of first RRT.

RESULTS: Overall, screening rates were low with the exception of diabetic eye exams. Prostate cancer screening, diabetic eye exams, and HbA1c testing were performed less often after onset of RRT compared to the year before (P<.05). Although screening rates before RRT improved considerably over the period of observation for these measures (P<.05), this was not the case once patients were on RRT.

CONCLUSIONS: Preventive health care interventions remain underutilized among RRT patients. Greater attention to such preventive measures could lead to significant improvements in the health status of such vulnerable patients. Thus, quality improvement of the general health care for patients on RRT should become a priority in renal health policy.

This is a preview of subscription content, access via your institution.

References

  1. U.S. Renal Data System. USRDS 2000 Annual Data Report, Chapter 9: Preventive Health Care Measures. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; June 2000.

  2. U.S. Renal Data System. USRDS 2000 Annual Data Report, Appendix A: Analytical Methods. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; June 2000.

  3. Epstein AM. Rolling down the runway: the challenges ahead for quality report cards. JAMA. 1998;279:1691–6.

    PubMed  Article  CAS  Google Scholar 

  4. Jones D, Hendricks A, Comstock C, et al. Eye examinations for VA patients with diabetes: standardizing performance measures. Int J Qual Health Care. 2000;12:97–104.

    PubMed  Article  CAS  Google Scholar 

  5. Zuvekas A, Hur R, Richmond D, Stevens D, Ayoama C, Modica C. Applying HEDIS clinical measures to community health centers: a feasibility study. J Ambul Care Manage. 1999;22:53–62.

    PubMed  CAS  Google Scholar 

  6. Capo KM, Rutledge DR. Applying managed care performance measures in community pharmacy-based outcomes research. J Am Pharm Assoc. 1999;39:388–94.

    CAS  Google Scholar 

  7. Winkelmayer WC, Glynn RJ, Levin R, Owen W Jr, Avorn J. Late referral and modality choice in end-stage renal disease. Kidney Int. 2001;60:1547–54.

    PubMed  Article  CAS  Google Scholar 

  8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

    PubMed  Article  CAS  Google Scholar 

  9. Klabunde CN, Potolsky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.

    PubMed  Article  CAS  Google Scholar 

  10. Anonymous. HEDIS 2001 Volume 2: Technical Specifications. Washington, DC: National Committee for Quality Assurance; 2000.

  11. Himmelstein DU, Woolhandler S, Hellander I, Wolfe SM. Quality of care in investor-owned vs not-for-profit HMOs. JAMA. 1999;282:159–63.

    PubMed  Article  CAS  Google Scholar 

  12. Inamoto H, Ozaki R, Matsuzaki T, Wakui M, Saruta T, Osawa A. Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients. Nephron. 1991;59:611–7.

    PubMed  CAS  Article  Google Scholar 

  13. New Jersey Department of Health and Senior Services. New Jersey HMOs: Performance Report. 1997. Available at http://www.state.nj.us/health/hmo/hmoreport.htm. Accessed June 24, 2002.

  14. Anonymous. Clinical Practice Guidelines NKF-DOQI. New York: National Kidney Foundation; 1997.

  15. Chertow G, Paltiel AD, Owen WF, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med. 1996;156:1345–50.

    PubMed  Article  CAS  Google Scholar 

  16. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93–9.

    PubMed  Article  CAS  Google Scholar 

  17. Wolfe RA, Held PJ, Hulbert-Shearon TE, Agodoa LY, Port FK. A critical examination of trends in outcomes over the last decade. Am J Kidney Dis. 1998;32:9S-15S.

    Google Scholar 

  18. Djavan B, Shariat S, Ghawidel K, et al. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology. 1999;53:1169–74.

    PubMed  Article  CAS  Google Scholar 

  19. Holley JL. Nephrologists as primary care providers: a review of the issues. Am J Kidney Dis. 1998;31:574–83.

    PubMed  CAS  Google Scholar 

  20. Bender FH, Holley JL. Most nephrologists are primary care providers for chronic dialysis patients: results of a national survey. Am J Kidney Dis. 1996;28:67–71.

    PubMed  CAS  Google Scholar 

  21. Holley JL, Nespor SL. Nephrologist-directed primary health care in chronic dialysis patients. Am J Kidney Dis. 1993;21:628–31.

    PubMed  CAS  Google Scholar 

  22. Latos D. Combining nephrology and primary care: not a black and white issue. Nephrol News Issues. 1994;8:19–22, 26.

    PubMed  CAS  Google Scholar 

  23. Lazarus JM. Triage expert or primary care physician? Nephrol News Issues. 1994;8:19, 21–23, 26.

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Wolfgang C. Winkelmayer MD, ScD.

Additional information

This work was supported by a grant (R0-1-HS09398) from the Agency for Health Care Policy and Research. Additional support was provided by the Health Care Financing Administration.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Winkelmayer, W.C., Owen, W., Glynn, R.J. et al. Preventive health care measures before and after start of renal replacement therapy. J GEN INTERN MED 17, 588–595 (2002). https://doi.org/10.1046/j.1525-1497.2002.11021.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.2002.11021.x

Key words

  • end-stage renal disease
  • quality management
  • preventive care
  • diabetes mellitus
  • mammography
  • hemoglobin A1C